Dr. Feng Yin, MD

Dr. Yin practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Yin's NPI, 1750795282, was assigned on June 12, 2014. Dr. Yin's Texas license number on file is T9827.

Dr. Yin's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Yin's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Yin practices. Vendor and product names are available with a free account.

Anatomic pathology and clinical pathology is Dr. Yin's primary specialty in the NPI Registry, under taxonomy code 207ZP0102X. Dr. Yin is board certified in pathology - anatomic/pathology - clinical by the American Board of Pathology. Dmand AI has Dr. Yin's licenses on file in 4 states: Texas, Missouri, Florida and Oklahoma.

CMS data shows 2,459 Medicare services from Dr. Yin across 16 procedure codes in 2024, for 655 Medicare patients. Medicare paid $81,377 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 655 Medicare patients who saw Dr. Yin in 2024. The largest group is 65 to 74, with 388 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Yin's median patient age at 64, with 46% women.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Yin for performance year 2024, reported as part of a group. Dr. Yin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 20 papers to Dr. Yin, published from 2016 to 2025. 2023 was the busiest year, with 3. The most frequent topics are Adenocarcinoma, Adaptor Proteins, Signal Transducing and Biomarkers, Tumor. Dr. Yin has published most often in Anticancer Res. Dr. Yin's most frequent co-authors are Jaffer A. Ajani, MD, Qiong Gan, MD and Veysel Tahan, MD.

CMS Open Payments shows 2 general payments to Dr. Yin from 1 drug or device company from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Astellas Pharma US Inc paid the most, $263.

Dr. Yin is in network with 5 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. HMO plans come from the most carriers, 4. Check the plan with the practice before a visit.